Elron Ventures Ltd · TASE:ELRN
Elron Ventures — Elron Electronic Industries — Investor Presentation (May 2015)
34 slides from Elron Ventures's investor presentation, May 15, 2015
Slide 1: Discover. Innovation
DISCOVER. INNOVATION May 2015
Slide 2: Disclaimer
This presentation is for information purposes only. By this presentation, Elron does not intend to solicit offers to purchase its securities and the presentation does not constitute an invitation to receive such offers. Elron may make improvements and/or changes in the features or content presented
Slide 3: Discover. Elron
DISCOVER. ELRON
Slide 4: Operational holding company in the VC space
OPERATIONAL HOLDING COMPANY IN THE VC SPACE WE SPECIALIZEIN MEDICAL DEVICE TECHNOLOGIES WITHSIGNIFICANT EXIT POTENTIAL + WE HAVE 50 YEARS EXPERIENCE IDENTIFYING OPPORTUNITIES, BUILDING TECHNOLOGY LEADERS, AND EXITING HOLDINGS + WE INVEST PRIMARILY IN EARLY STAGE COMPANIES +WE RELY ON A PROVEN STRATE
Slide 5: Performance in Q1/15
PERFORMANCE IN Q1/15: * Including RDC
Slide 6: Holdings in companies and book value at March 31, 2015
Holdings in companies 1 Book value at Mar. 31, 2015 ($m) Amount invested ($m) Associates and consolidated companies: Pocared 14.2 41.8 BrainsGate 1.6 24.5 Others 5.2 20.0 Companies presented at fair value: Notal Vision 13.8 8.5 Jordan Valley 9.0 8.1 Others 4.5 18.6 Total Holdings 48.3 121.5 Cash (as
Slide 7: Discover. BrainsGate
DISCOVER. BRAINSGATE
Slide 8: Our investment: $25M, our holding: 30%
OUR INVESTMENT: $25M OUR HOLDING: 30%
Slide 9: Stroke burden statistics
Sources: American Heart Association: Heart Disease and Stroke Statistics Report - 2015; BrainsGate website: http://brainsgate.com/eng/page.php?id=3&instance_id=9.
Slide 10: Stroke outcomes (mRS) and lifetime cost per patient
Sources: American Heart Association: Heart Disease and Stroke Statistics Report - 2010, 2015; CDC website: http://www.cdc.gov/stroke/facts.htm. mRS Average Lifetime Cost Per Stroke Patient Sources: Samsa et al, Performing Cost-Effectiveness Analysis by Integrating Randomized Trial Data with a Compre
Slide 11: Thrombolysis treatment rates in stroke
Source: American Heart Association: Temporal Trends in Patient Characteristics and Treatment With Intravenous Thrombolysis Among Acute Ischemic Stroke Patients at Get With the Guidelines-Stroke Hospitals, Schwamm, Circ Cardiovasc Qual Outcomes. 2013;6:543-549.
Slide 12: Limits of current stroke treatments
Sources: Adams HP, et al (2003) Stroke 34 , 1056-83; del Zoppo GJ, et al (2009) Stroke 40 , 2945-48.
Slide 13: Recent endovascular therapy trial results
Sources: Broderick JP, et al (2013) New England Journal of Medicine 368 (10), 893-903; Ciccone A, et al (2013) New England Journal of Medicine 368 (10), 904-13; Kidwell CS, et al (2013) New England Journal of Medicine 368 (10), 914-23; Berkhemer OA, et al (2015) New England Journal of Medicine 372 (
Slide 14: BrainsGate: alternate therapy expanding treatment window to 24 hours
BRAINSGATE: ALTERNATE THERAPY THAT EXPANDS THE TREATMENT WINDOW TO 24 HOURS ELECTRODE: 24-HOUR TREATMENT WINDOW * Electrical stimulation of the SPG (a nerve center behind the nasal cavity) using a miniature electrode + The electrode’s activation induces dilation of cerebral blood vessels, and augmen
Slide 15: BrainsGate ISS system components
BrainsGate’s ISS is an investigational device, not approved for marketing. GuideView SPG (sphenopalatine ganglion) = supplies parasympathetic innervation to the anterior cerebral circulation and some of the posterior circulation Transmitter = emits RF waves which energize the implant Implant = deliv
Slide 16: FDA pivotal trial design
Primary outcome Distribution of patients across mRS, according to sliding dichotomous analysis,* at 90 days Study design Multicenter, randomized, double blind, sham control Estimated enrollment 800-1000 (to date ~540 patients have been enrolled) Inclusion criteria Aged 40-85, acute ischemic stroke i
Slide 17: Discover. Pocared
DISCOVER. POCARED
Slide 18: Our investment: $42M, our holding: 53%
OUR INVESTMENT: $42M OUR HOLDING: 53%
Slide 19: Limits of traditional microbiology testing
Over-/mis-prescribing antibiotics while awaiting lab results (promotes antibiotic resistance) Costly lab tests Since the 19 th century, microbiology testing has been done by culturing bacteria in petri dishes Expensive: Requires reagents and skilled lab technicians Manual: Prone to human error, limi
Slide 20: Antibiotic resistance timeline
1940 1959 1968 1962 1979 1988 1998 1987 1996 2001 2004 2011 Resistance identified Antibiotic introduced Sources: CDC, Antibiotic Resistance Threats in the United States, 2013; “FDA’s Take on the Executive Order and National Strategy to Combat Antibiotic-Resistant Bacteria”, posted on September 18, 2
Slide 21: Microbiology lab: last lab to implement full automation
THE MICROBIOLOGY LAB: THE LAST LAB TO IMPLEMENT FULL AUTOMATION © FEWER SKILLED WORKERS. ® HIGHER THROUGHPUT ° The average age of the lab workforce in the Testing volumes are increasing 10-35% per U.S. is about 50, and increasing year, due to factors such as: About 70% of training programs have clos
Slide 22: P-1000 Analyzer and Sample Processor
The P-1000 Analyzer is investigational in the U.S., and CE-marked in the EU. The Sample Processor is exempt from regulatory approvals.
Slide 23: Pocared clinical study design
Primary outcome Agreement of the P-1000 quantification and identification method compared with the standard method (agreement = >90% sensitivity & specificity for each pathogen) * Estimated collection 19,500 samples (to date ~9,100 samples have been collected) Pathogens E. Coli, Chlamydia, Klebsiell
Slide 24: Next applications for Pocared's P-1000
THE NEXT APPLICATIONS FOR POCARED'S P-1000: 1 THROAT SWABS (streptococci) 2 een (MRSA/MSSA) 4am tests in the U.S. annually 8m tests in the U.S. annually STATUS: clinical validation, ready for regulatory studies STATUS: clinical feasibility 3 BLOOD CULTURES | ANTIBIOTIC RESISTANCE (sepsis) (rapid AST
Slide 25: Discover. Notal Vision
DISCOVER. NOTAL VISION
Slide 26: Our investment: $8.5M, our holding: 21%
OUR INVESTMENT: $8.5M OUR HOLDING: 21%
Slide 27: AMD destroys sharp, central vision
AMD destroys sharp, central vision, necessary for common tasks such as facial recognition, driving, reading, & watching television Sources: Brown DM, et al (2006). New England Journal of Medicine 355 , 1432-44; Slakter JS & Stur M (2005). S urvey of Ophthalmology 50 , 263-73; Gehrs KM, et al (2006).
Slide 28: Unpredictable wet AMD and the home monitoring solution
It is not possible to predict who will develop wet AMD, and if so, when Dry AMD patients are monitored once or twice a year, in routine check-ups at the eye doctor Wet AMD can be treated , but due to late diagnosis, 64% of eyes end with dysfunctional vision even after treatment Sources: Wittenborn J
Slide 29: ForeseeHome: saving the patient's vision before it's too late
FORESEEHOME: SAVING THE PATIENT'S VISION BEFORE IT’S TOO LATE BESS Ss FDA CLEARED CE MARKED CLINICALLY PROVEN 2CPT CODES ADOPTED IN THE AAOS'’s CLINICAL GUIDELINES AREDS2: Notal Vision conducted a trial in collaboration with the NIH on 3,520 patients in 44 eye clinics: 94% of patients who used the d
Slide 30: Notal Vision in negotiations with CMS
NOTAL VISION IS IN NEGOTIATIONS WITH CMS AND SEVERAL REGIONAL MEDICARE CARRIERS REGARDING COVERAGE AND PAYMENT
Slide 31: Discover. Pipeline
DISCOVER. PIPELINE
Slide 32: CartiHeal and Kyma investments
OUR INVESTMENT: $6.3M OUR HOLDING: 34% OUR INVESTMENT: $5.7M OUR HOLDING: 26% CartiHeal’s and Kyma’s devices are investigational in the U.S., and CE-marked in the EU.
Slide 33: Summary: proven expertise in identifying opportunities
SUMMARY: 1 WE HAVE PROVEN EXPERTISE IN IDENTIFYING OPPORTUNITIES, BUILDING TECHNOLOGY LEADERS, AND EXITING HOLDINGS WE ANTICIPATE SIGNIFICANT DEVELOPENTS IN OUR MATURE COMPANIES THIS YEAR NJ 3 OUR CURRENT MARKET VALUE IS $140M, AND OUR LIQUID RESOURCES BALANCE |S $113M
Slide 34: Elron. Opportunity. Thank you.
ELRON. OPPORTUNITY Thank you.
Elron Electronic Industries — Investor Presentation (May 2015) on 6ix